TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14513268
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU) plus calcium (500 mg)
Study: 11688520
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) plus Epirubicin (E) plus Taxol (T) (GET)
Study: 11688520
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy (HDCT) after GET
Study: 8851643
Drug: Midday light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midday light therapy
Study: 8851643
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light therapy
Study: 8851643
Drug: Evening light
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening light therapy
Study: 8851643
Drug: Light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light treatment (general)
Study: 540522
Drug: 0.05% clobetasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasone butyrate cream
Study: 21926601
Drug: Hydrocortisone 200
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 200 mg/day (HC group)
Study: 19036894
Drug: PRO-CHO (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-CHO (1.2 g CHO + 0.4 g protein x kg(‐1) x h(‐1))
Study: 19036894
Drug: L-CHO (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-CHO (1.2 g CHO x kg(‐1) x h(‐1))
Study: 19036894
Drug: H-CHO (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-CHO (1.6 g CHO x kg(‐1) x h(‐1))
Study: 19036894
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g CHO x kg(‐1) x h(‐1)
Study: 17434014
Drug: Quin-Lng (levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quin-Lng (levonorgestrel 6 mg)
Study: 17434014
Drug: Quin-Ng (quinestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quin-Ng (quinestrol 3 mg and norgestrel 12 mg)
Study: 11307656
Drug: Tramadol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1.5 mg.kg‐1)
Study: 15352967
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g)
Study: 9720832
Drug: Nafarelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (200 microg intranasal, twice a day for 6 months)
Study: 30954360
Drug: Intravenous phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenobarbital (PB) at 10 mg/kg
Study: 30954360
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of normal saline)
Study: 30954360
Drug: Intravenous phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenobarbital (PB) at 10 mg/kg (after placebo failure)
Study: 19366489
Drug: Aripiprazole (partial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (partial agonist)
Study: 19366489
Drug: Antagonist antipsychotics
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist antipsychotics (risperidone or olanzapine)
Study: 16955110
Drug: Cefotaxime/heparin lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime/heparin lock (group I)
Study: 11211363
Drug: MTA behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA behavioral and medication treatments
Study: 11211363
Drug: MTA medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA medication treatments (with or without behavioral treatments)
Study: 11211363
Drug: Combined (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (medication and behavioral) treatments
Study: 2899236
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetylsalicylic acid (ASA) orally starting 12 h after admission and then intermittently every third day for one month
Study: 9431267
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetylsalicylic acid (ASA)
Study: 30922297
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg orally once daily for 6 weeks
Study: 19661078
Drug: CARET intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARET intervention (30 mg beta-carotene + 25,000 IU retinyl palmitate) with additional supplements
Study: 19661078
Drug: Postintervention phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postintervention phase (CARET + other supplements)
Study: 19661078
Drug: CARET intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARET intervention (30 mg beta-carotene + 25,000 IU retinyl palmitate)
Study: 16961710
Drug: Killed Mycobacterium
Normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed Mycobacterium vaccae (1 mg)
Study: 16961710
Drug: Killed Mycobacterium
Normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed Mycobacterium vaccae (0.1 mg)
Study: 11197402
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 5 ppm
Study: 11147718
Drug: buserelin MP
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: buserelin MP 1.8 mg
Study: 11147718
Drug: leuprolide 1.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide 1.88 mg
Study: 3096429
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin injections (five or six daily)
Study: 3096429
Drug: Conventional twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional twice daily insulin injections
Study: 24918556
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg daily for 8 weeks
Study: 24918556
Drug: Lymecycline 300
Normalized name: lymecycline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 300 mg daily for 8 weeks
Study: 18534327
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (160 mg twice daily)
Study: 15920008
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for acute lymphoblastic leukemia (ALL)
Study: 9893189
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone 100 microg administered twice daily for 4 weeks
Study: 1885267
Drug: 100ml orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml orange juice with dissolved K‐ and Mg‐phosphates (K, 40mmol; Mg, 17.5mmol; HPO4, 35mmol)
Study: 1885267
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of ephedrine intravenously, 0.25mg/kg body weight
Study: 6395614
Drug: Metronidazole (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (two-dose perioperative course, rectally administered)
Study: 6395614
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metronidazole and T-tube suction drainage
Study: 27112632
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream applied 3 times per week for 12 weeks
Study: 20626240
Drug: Metformin 2550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2550 mg/day
Study: 19056578
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (75 g)
Study: 12576260
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg per day) + Conjugated estrogen cream (0.5 g)
Study: 12576260
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg per day) + Nonhormonal moisturizer
Study: 12576260
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Conjugated estrogen cream (0.5 g)
Study: 8723144
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 200 mg/day
Study: 8723144
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 600 mg/day
Study: 1653795
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 x 20 mg/day)
Study: 1653795
Drug: Hydergine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine (2 x 2 mg/day)
Study: 1653795
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nifedipine 20 mg/day and Hydergine 2 mg/day, twice daily each)
Study: 6661351
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg/day
Study: 2978324
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg/day
Study: 15683500
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg/day
Study: 28294173
Drug: UHT dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: UHT dairy milk (1.5 l for 21 days)
Study: 28294173
Drug: PAST dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAST dairy milk (1.5 l for 21 days)
Study: 22568828
Drug: FPSM/BDP (Fluticasone/Salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPSM/BDP (Fluticasone/Salmeterol + HFA-beclomethasone diproprionate 200 µg twice daily)
Study: 22568828
Drug: FPSM/PRED (Fluticasone/Salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPSM/PRED (Fluticasone/Salmeterol + Prednisolone 25 mg day(‐1) for 1 week)
Study: 22568828
Drug: FPSM/FP (Fluticasone/Salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPSM/FP (Fluticasone/Salmeterol + Fluticasone 250 µg twice daily)
Study: 22568828
Drug: HFA-BDP (HFA-beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (HFA-beclomethasone diproprionate 200 µg twice daily)
Study: 20733587
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 to 100 mg, adjustable to 25 mg)
Study: 19330598
Drug: Micronized estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized estradiol (E2) 0.5 mg
Study: 19330598
Drug: Micronized estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized estradiol (E2) 1.0 mg
Study: 9284696
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate therapy (400 mg/day for 2 weeks followed by 500 mg/day elemental calcium for 11 weeks)
Study: 8335459
Drug: Natural interferon
Normalized name: interferon beta natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural interferon beta (5 million IU, 30-min i.v. infusion, three times weekly for 6 months)
Study: 3594459
Drug: Oxiracetam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (2 X 800 mg, orally, bid for 8 weeks)
Study: 27217217
Drug: Monovalent oral
Normalized name: Rotarix, monovalent oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent oral rotavirus vaccine (RV1)
Study: 21302490
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + Smecta + Umbilical application of Lunxieting Paste (LXT) (Group C)
Study: 21302490
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + Smecta (Group B)
Study: 21302490
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (Group A)
Study: 17967831
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg i.v. every 6 weeks)
Study: 12562457
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei supplementation (10^8 colony-forming units/mL L. casei, thrice daily during meals for 3 weeks)
Study: 10801757
Drug: Intracoronary gamma-radiation
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary gamma-radiation therapy (15 Gy)
Study: 8633574
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (660 mg/day)
Study: 1455853
Drug: Polnitrin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polnitrin (5 mg nitroglycerin buccal tablet)
Study: 1455853
Drug: Foreign analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foreign analogue (5 mg nitroglycerin buccal tablet)
Study: 1455853
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.5 mg tablet)
Study: 3968773
Drug: Adenosine monophosphate
Normalized name: Adenosine monophosphate
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine monophosphate (AMP) treatment
Study: 24148131
Drug: ARV initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ARV initiation after tuberculosis treatment onset
Study: 15860983
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of amlodipine besylate/benazepril HCl
Study: 8979626
Drug: Enalapril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril monotherapy
Study: 6213250
Drug: Fenoterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (2 mg)
Study: 6213250
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide and fenoterol (combination)
Study: 6213250
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide and fenoterol (both drugs)
Study: 30762760
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) tranexamic acid (TXA) 20 mg/kg before TKA
Study: 30762760
Drug: Intra-articular (IA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular (IA) tranexamic acid (TXA) 3.0 g after TKA
Study: 30762760
Drug: Combined IV
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IV (20 mg/kg) and IA (3.0 g) tranexamic acid (TXA)
Study: 27856940
Drug: Investigational cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational cigarettes with 0.4 mg/g nicotine content
Study: 27856940
Drug: Investigational cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational cigarettes with 0.4 mg/g high tar nicotine content
Study: 27856940
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15.8 mg/g nicotine content)
Study: 19164458
Drug: FDG-PET after
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET after two cycles of chemotherapy
Study: 17556905
Drug: Indoramin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (25 mg)
Study: 8325064
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 0 mg
Study: 8325064
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 1 mg
Study: 8325064
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 4 mg
Study: 8325064
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 10 mg
Study: 30539864
Drug: Concurrent 125I
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent 125I implantation and chemotherapy
Study: 25027638
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors in HIV-positive patients with lipodystrophy syndrome
Study: 25027638
Drug: HIV-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive patients not using protease inhibitors
Study: 25027638
Drug: HIV-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive patients treated with protease inhibitors but without posterior ankle pain
Study: 20547525
Drug: Postpartum screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum screening for type 2 diabetes (T2DM) via oral glucose tolerance tests (OGTTs)
Study: 18713922
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TDN) 30 (21 mg nicotine) patches administered 1 h before induction of anesthesia and for two additional days after surgery
Study: 18713922
Drug: Inert (sham)
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert (sham) patches administered 1 h before and for 2 days after surgery
Study: 16296612
Drug: 2% SDBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% SDBS ointment
Study: 16296612
Drug: 2% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% metronidazole ointment
Study: 12675669
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg diazoxide
Study: 31770068
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine Lot 1
Study: 31770068
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine Lot 2
Study: 31770068
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine Lot 3
Study: 31268126
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout beverage (full dose, n=25)
Study: 31268126
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout beverage (one-half dose, n=35)
Study: 31268126
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout beverage (one-fifth dose, n=55)
Study: 24553678
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections into the subscapularis muscle
Study: 24553678
Drug: Scapulothoracic bursa
Normalized name: Capsella bursa-pastoris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapulothoracic bursa injections
Study: 19751376
Drug: Caffeine (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (combined treatment plus prophylaxis)
Study: 17521032
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro fine particle dose for Neohaler (NH) with 100-microg formulation
Study: 17521032
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro fine particle dose for AeroChamber Plus (AP) with 100-microg formulation
Study: 17521032
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro fine particle dose for Neohaler (NH) with 50-microg formulation
Study: 17521032
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro fine particle dose for AeroChamber Plus (AP) with 50-microg formulation
Study: 15209624
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + eradication (omeprazole 20 mg b.i.d. and amoxicillin 500 mg q.i.d. for 2 weeks)
Study: 15209624
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + placebo eradication
Study: 11685360
Drug: Knee splint
Normalized name: Knee Splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee splint (special resistance-controlled knee splint for 15 min three times daily)
Study: 7975843
Drug: Edmonston-Zagreb (EZ)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (EZ) virus at age 4-8 months (medium dose: 40,000 p.f.u. and high dose: 150,000 p.f.u.)
Study: 7975843
Drug: Schwarz (SW)
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz (SW) virus at age 9-12 months (standard dose: 5000 p.f.u.)
Study: 10460069
Drug: Clomipramine 75
Normalized name: clomipramine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 75 mg/day
Study: 800970
Drug: tolmetin (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolmetin (1600 mg/day)
Study: 800970
Drug: phenylbutazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylbutazone (400 mg/day)
Study: 28619301
Drug: Hydrocollator-based hot
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocollator-based hot pack therapy (active control)
Study: 23860345
Drug: D‐MPH‐ER 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐MPH‐ER 30 mg
Study: 23860345
Drug: D‐MPH‐ER 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐MPH‐ER 20 mg